These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 34380074)
1. Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition. Mani C; Tripathi K; Chaudhary S; Somasagara RR; Rocconi RP; Crasto C; Reedy M; Athar M; Palle K Neoplasia; 2021 Sep; 23(9):1002-1015. PubMed ID: 34380074 [TBL] [Abstract][Full Text] [Related]
2. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904 [TBL] [Abstract][Full Text] [Related]
3. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272 [TBL] [Abstract][Full Text] [Related]
4. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143 [TBL] [Abstract][Full Text] [Related]
5. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564 [TBL] [Abstract][Full Text] [Related]
7. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344 [TBL] [Abstract][Full Text] [Related]
8. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272 [TBL] [Abstract][Full Text] [Related]
9. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650 [TBL] [Abstract][Full Text] [Related]
10. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594 [TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
12. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Lin ZP; Al Zouabi NN; Xu ML; Bowen NE; Wu TL; Lavi ES; Huang PH; Zhu YL; Kim B; Ratner ES Sci Rep; 2021 Apr; 11(1):8042. PubMed ID: 33850183 [TBL] [Abstract][Full Text] [Related]
13. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT Cells; 2020 Apr; 9(4):. PubMed ID: 32276472 [TBL] [Abstract][Full Text] [Related]
14. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128 [TBL] [Abstract][Full Text] [Related]
15. GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Ikeuchi H; Matsuno Y; Kusumoto-Matsuo R; Kojima S; Ueno T; Ikegami M; Kitada R; Sumiyoshi-Okuma H; Kojima Y; Yonemori K; Yatabe Y; Takamochi K; Suzuki K; Yoshioka KI; Mano H; Kohsaka S Oncogene; 2024 Oct; 43(41):3037-3048. PubMed ID: 39095584 [TBL] [Abstract][Full Text] [Related]
16. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
17. FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism. Miao H; Meng H; Zhang Y; Chen T; Zhang L; Cheng W Cell Death Differ; 2024 Apr; 31(4):497-510. PubMed ID: 38374229 [TBL] [Abstract][Full Text] [Related]
18. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581 [TBL] [Abstract][Full Text] [Related]
19. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614 [TBL] [Abstract][Full Text] [Related]
20. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]